Details for Patent: 9,539,234
✉ Email this page to a colleague
Which drugs does patent 9,539,234 protect, and when does it expire?
Patent 9,539,234 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has one hundred and forty-seven patent family members in twenty-three countries.
Summary for Patent: 9,539,234
| Title: | Treatment of circadian rhythm disorders |
| Abstract: | Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
| Inventor(s): | Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
| Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
| Application Number: | 14/688,301 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,539,234 |
|
Patent Claim Types: see list of patent claims | Use; |
More… ↓ |
Drugs Protected by US Patent 9,539,234
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 9,539,234 | ⤷ Subscribe | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR | ⤷ Subscribe | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 9,539,234 | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR | ⤷ Subscribe | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 9,539,234 | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,539,234
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013211878 | ⤷ Subscribe | |||
| Australia | 2013211880 | ⤷ Subscribe | |||
| Australia | 2013361459 | ⤷ Subscribe | |||
| Australia | 2015206797 | ⤷ Subscribe | |||
| Australia | 2016204178 | ⤷ Subscribe | |||
| Australia | 2016204217 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
